Hybrid immunity in immunocompromised patients with CLL after SARS-CoV-2 infection followed by booster mRNA vaccination

Blood. 2022 Dec 1;140(22):2403-2407. doi: 10.1182/blood.2022016815.

Lisa Blixt^{1

2}, Yu Gao³, David Wullimann³, Hanna Murén Ingelman-Sundberg^{2

4}, Sandra Muschiol^{5

6}, Katie Healy⁷, Gordana Bogdanovic^{5

6}, Elisa Pin⁸, Peter Nilsson⁸, Christian Kjellander^{9

10}, Alba Grifoni¹¹, Alessandro Sette^{11

12}, Margaret Sällberg Chen⁷, Hans-Gustaf Ljunggren³, Marcus Buggert³, Lotta Hansson^{1

2}, Anders Österborg^{1

2}

¹ Department of Hematology, Karolinska University Hospital Solna, Stockholm, Sweden.
² Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden.
³ Department of Medicine Huddinge, Center for Infectious Medicine, Karolinska Institutet, Stockholm, Sweden.
⁴ Department of Oncology, Karolinska University Hospital Solna, Stockholm, Sweden.
⁵ Department of Clinical Microbiology, Karolinska University Hospital Solna, Stockholm, Sweden.
⁶ Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet, Stockholm, Sweden.
⁷ Department of Dental Medicine, Karolinska Institutet, Huddinge, Sweden.
⁸ Department of Protein Science, SciLifeLab, KTH Royal Institute of Technology, Stockholm, Sweden.
⁹ Department of Laboratory Medicine, Karolinska Institutet, Stockholm, Sweden.
¹⁰ Department of Internal Medicine, Capio St Göran Hospital, Stockholm, Sweden.
¹¹ Center for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology, La Jolla, CA.
¹² Division of Infectious Diseases and Global Public Health, Department of Medicine, University of California, San Diego, La Jolla, CA.

No abstract available

Publication types